The interplay between bone, muscle and adipose tissue — is there a role for potential new metabolic biomarker?

ABSTRACT
Recent studies in mice and humans have shown the tight connection between bone and muscle tissues. Physical activity affects the function of osteocytes, mature bone cells, stimulating the synthesis of several hormone-like myokines in skeletal muscles. Anabolic action of physical exercise on bone is mediated by a myokine called irisin. This protein was initially assigned to regulate glucose homeostasis in humans but recently the influence of irisin on bone and adipose tissue metabolism was also demonstrated. In the human blood, irisin occurs in different forms, free or complexed, glycosylated and non-glycosylated which makes a reliable and reproducible measurement of this protein a crucial issue for the clinical interpretation of experimental findings. In humans, irisin was shown to inversely correlate with the prevalence of bone fractures. Data obtained so far suggest that irisin could be a potential target for the treatment of osteoporosis and play an important role in the bone healing process.

Key words: bone, muscle, adipose tissue, myokines, irisin, bone fractures
Irisin was initially assigned to regulate glucose homeostasis in humans, in particular in individuals with type 2 diabetes [8–10]. Recently, an influence of irisin on bone and adipose tissue metabolism was also reported [11]. Although, serum level of irisin was related to a wide range of clinical disorders the studies in humans reported inconclusive and sometimes discrepant results [12, 13]. It is clear that further well designed studies are necessary for clarification of effects of irisin on different tissues.

So far, most human studies reported a weak but positive association of irisin with body mass and markers of insulin resistance [4]. Interestingly, a direct correlation was observed between blood irisin levels, fasting insulin and glucose in healthy and obese subjects, children and women with polycystic ovary syndrome, but not in diabetics. It is worth to note that secretion of irisin was not affected by food intake [14]. Unexpectedly, in most previous studies carried on in patients with prediabetes or type 2 diabetes lower irisin levels, compared to normoglycemic subjects, were observed. The mechanism behind this phenomenon has not been elucidated yet. Similarly, the uniform data are lacking regarding the possible role of irisin in metabolic syndrome, liver and cardiovascular diseases [4].

It was postulated that physiological function of irisin in different tissues may depend on its effective concentration and type of cellular receptors [5]. Studies in mice bring discrepant results demonstrating positive or negative effects of irisin on bone. Kim et al. reported on irisin functional receptors on osteocytes and adipocytes in mice. These irisin receptors belong to alpha-V class of integrins through which irisin promotes bone remodelling by stimulating sclerostin expression. Direct induction of sclerostin, an osteocyte-derived signalling molecule inhibiting bone formation, by irisin was shown in vitro and in vivo. Based on this observation the authors suggested that irisin could be a potential target for treatment of osteoporosis [5].

Recent findings from animal experiments demonstrated the anabolic action of irisin on bone tissue [2, 15, 16]. Zhang et al showed that exercise-induced secretion of irisin increases osteoblastogenesis and decrease osteoclastogenesis in experimental mice [16]. Colaianni et al reported that irisin may increase cortical bone mass [2, 15]. In addition they observed that treatment with recombinant irisin prevented bone loss and protected against muscle atrophy in animals subjected to immobilization which may be an important step forward on the way to search for novel therapies for elderly and physically disable patients [17].

Irisin was shown to inversely correlate with the prevalence of bone fractures in postmenopausal women with low bone mass [18]. Irisin levels were lower than normal in diabetics with increased risk of osteoporosis and bone fractures suggesting its role in prevention of fractures [19]. It is likely that irisin may also play a role in bone healing process.

The first study performed in adult patients with hip fractures in which irisin concentration was measured in the serum and irisin presence was showed immunohistochemically in bone tissues samples, taken during arthroplasty, revealed that concentration of this myokine increases during the bone union process [21]. Patients included in this study were carefully selected based on the exclusion criteria like bone metabolic diseases, malignancy, diabetes, kidney disease and hormonal disorders. All study patients underwent hip arthroplasty within 24 hours after admission to the hospital. Interestingly, the mean value of serum irisin was found to be significantly higher 60 days after operation, compared to the concentrations at baseline, 1 day and at 15 days after operation. These findings led authors to conclusion that irisin may positively affect bone healing which is of importance in the light of constant search for factors affecting bone healing process.

It is not surprising that the relationship between irisin and estradiol level in elderly individuals was also investigated. It was reported that the synthesis of sclerostin and irisin may be influenced by estradiol in postmenopausal overweight women with osteoporosis [5, 22]. In obese subjects a direct relationship of irisin with estradiol level, muscle mass and insulin sensitivity was observed [20, 22]. On the contrary, older age and body fat was negatively correlated with irisin and sclerostin in adults with prediabetes [20]. A possible link of metabolic impairment biomarkers with bone metabolism in children has not been extensively investigated however, recently a negative effect of inflammation and insulin resistance on bone development in young girls was postulated [23]. Moreover, in children with diabetes mellitus type 1 the detrimental impact of increased sclerostin on bone formation has been shown [24]. Taken together these data provide insight into the complex regulatory interplay of bone, muscle and adipose tissues.

Continuous bone remodelling essential for longitudinal growth of skeleton in children, motion, maintaining of bone mass, repairing damages and fracture healing is an energy consuming process, therefore, must be linked to energy metabolism, in particular to glucose metabolism [25, 26]. The utilization of glucose by bone tissues is approximately half of that by adipose tissue and much lower than by muscles [1]. It is extremely interesting that the anabolic action of parathyroid hormone on bone, as demonstrated by Esen et al, was through increase of aerobic glycolysis (glucose consumption and production of lactate) via IGF-1 signalling and the same is true for irisin as anabolic agent [27, 28]. The anabolic effect of irisin on bone is particularly dependent on glucose metabolism, moreover irisin plays...
an important role in the regulation of energy expenditure
in different metabolic conditions [1, 28].

Whether irisin, a novel hormone-like myokine, plays a unique role linking bone, muscle and adipose tissue metabolism in humans remains to be investigated. Further studies are necessary to clarify the interplay between irisin and potential other exercise-induced mediators released by bone, adipose and muscle cells.

Abbreviations: RANK-receptor activator of nuclear factor kappaβ

References

1. Zhang D, Bae C, Lee J, et al. The bone anabolic effects of irisin are through preferential stimulation of aerobic glycolysis. Bone. 2018; 114: 150–160, doi: 10.1016/j.bone.2018.05.013, indexed in PubMed: 29775761.

2. Colaianni G, Cuscito C, Mongelli T, et al. The myokine irisin increases cortical bone mass. Proc Natl Acad Sci U S A. 2015; 112(39): 12157–12162, doi: 10.1073/pnas.1516622112, indexed in PubMed: 26374841.

3. Jedrychowski MP, Wrann CD, Jedrychowski M, et al. Detection and Quantitation of Circulating Human Irisin by Tandem Mass Spectrometry. Cell Metab. 2015; 22(4): 734–740, doi: 10.1016/j.cmet.2015.08.001, indexed in PubMed: 26279351.

4. Perakakis N, Triantafyllou GA, Fernández-Real JM, et al. Physiology and role of irisin in glucose homeostasis. Nat Rev Endocrinol. 2017; 13(6): 324–337, doi: 10.1038/nrendo.2016.221, indexed in PubMed: 28215112.

5. Kim H, Wrann CD, Jedrychowski M, et al. Irisin Mediates Effects on Bone and Fat via c-Jun N-terminal Kinase Receptors. Cell. 2018; 175(7): 1756–1768, e17, doi: 10.1016/j.cell.2018.10.025, indexed in PubMed: 30550785.

6. Soininen S, Sidoroff F, Lindi V, et al. Body composition and associated biomarkers as determinants of bone mineral density in children 6-8 years of age - The Physical Activity and Nutrition in Children (PRINIC) study. Bone Abstracts. 2017. doi: 10.1530/boneabs.6.0014.

7. Löffler D, Müller U, Scheuermann K, et al. Serum irisin levels are regulated by acute strenuous exercise. J Clin Endocrinol Metab. 2015; 100(4): 1289–1299, doi: 10.1210/jc.2014-2929, indexed in PubMed: 25629801.

8. Park KH, Zacherenko L, Brinketter M, et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome. J Clin Endocrinol Metab. 2013; 98(12): 4899–4907, doi: 10.1210/jc.2013-2373, indexed in PubMed: 24057291.

9. Hu H, Panagiotou G, Mougiou V, et al. FNDC5 and irisin in humans: I. Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metabolism. 2012; 61(12): 1725–1738, doi: 10.1016/j.metabol.2012.09.002, indexed in PubMed: 23018146.

10. Kurdiova T, Balaz M, Vican V, et al. Effects of obesity, diabetes and exercise on FNDC5 gene expression and irisin release in human skeletal muscle and adipose tissue: in vivo and in vitro studies. J Physiol. 2014; 592: 1091–1107.

11. Grygiet-Gorniak B, Puszczewicz M. A review on irisin, a new protagonist that mediates muscle-adipose-bone-neuron connectivity. Eur Rev Med Pharmacol Sci. 2017; 21(20): 4867–4893, indexed in PubMed: 29131244.

12. Bowenald L. Use it or lose it to age: A review of bone and muscle communication. Bone. 2019; 120: 212–218, doi: 10.1016/j.bone.2018.11.002, indexed in PubMed: 30408611.

13. Polyzos SA, Anastasilakis AD, EfstatiadouZA, et al. Irisin in metabolic diseases. Endocrine. 2018; 59(2): 260–274, doi: 10.1007/s12020-017-1476-1, indexed in PubMed: 29170905.

14. Huerta AE, Prieto-Hontoria PL, Fernández-Galicia M, et al. Circulating irisin and glucose metabolism in overweight/obese women: effects of α-lipoic acid and eicosapentaenoic acid. J Physiol Biochem. 2015; 71(3): 547–558, doi: 10.1016/j.jphysiol.2015.01-0400-5, indexed in PubMed: 25802474.

15. Colaianni G, Mongelli T, Colucci S, et al. Crosstalk Between Muscle and Bone Via the Muscle-Myokine Irisin. Curr Osteoporos Rep. 2016; 14(4): 132–137, doi: 10.1007/s11914-016-0313-4, indexed in PubMed: 27269471.

16. Zhang J, Valverde P, Zhu X, et al. Exercise-induced irisin in bone and systemic irisin administration reveal new regulatory mechanisms of bone metabolism. Bone Res. 2017; 5: 16056, doi: 10.1038/bonesres.2016.56, indexed in PubMed: 28944087.

17. Colaianni G, Mongelli T, Cuscito C, et al. Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice. Sci Rep. 2017; 7(1): 2811, doi: 10.1038/s41598-017-02557-8, indexed in PubMed: 28588307.

18. Anastasilakis AD, Polyzos SA, Makras P, et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos Int. 2014; 25(6): 1633–1642, doi: 10.1007/s00198-014-2673-x, indexed in PubMed: 24599275.

19. Farr JN, Drake MT, Amin S, et al. In vivo assessment of bone quality in postmenopausal women with type 2 diabetes. J Bone Miner Res. 2014; 29(4): 787–796, doi: 10.1002/jbmr.2108, indexed in PubMed: 24123088.

20. Klapproecheontai N, Nimitphong H, Saetung S, et al. Circulating sclerostin and irisin are related and interact with gender to influence adiposity in adults with prediabetes. Int J Endocrinol. 2014; 2014: 281545, doi: 10.1155/2014/281545, indexed in PubMed: 25276128.

21. Serbest S, Tiftikci U, Tosun HB, et al. The Irisin Hormone Profile and Expression in Human Bone Tissue in the Bone Healing Process in Patients. Med Sci Monit. 2017; 23: 4278–4283, doi: 10.12659/msm.906293, indexed in PubMed: 28869754.

22. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98(4): E769–E778, doi: 10.1210/jc.2012-2749, indexed in PubMed: 23436919.

23. Hetherington-Rauth M, Bea JW, Blew RM, et al. Relationship of cardiometabolic risk biomarkers with DHA and ω3PCT bone health outcomes in young girls. Bone. 2019; 120: 452–458, doi: 10.1016/j.bone.2018.12.013, indexed in PubMed: 30572143.

24. Wędrychowicz A, Sztekko K, Starzyk JB. Sclerostin and its significance in osteoporosis. J Physiol. 2014; 592: 1091–1107.

25. Klangjareonchai T, Nimitphong H, Saito T, et al. Sclerostin and irisin signify a correlation between sclerostin and irisin with gender to influence bone metabolism. Bone Res. 2017; 5: 16056, doi: 10.1038/bone.2017.033, indexed in PubMed: 27459047.

26. Palermo A, Strollo R, Maddaloni E, et al. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin Endocrinol (Oxf). 2015; 82(4): 615–619, doi: 10.1111/cen.12672, indexed in PubMed: 25400208.